BioVectra and Keryx Biopharmaceuticals Enter Agreement for Ferric Citrate Production Expansion

About Keryx Biopharmaceuticals, Inc. Keryx Biopharmaceuticals, Inc., with headquarters in Boston, Massachusetts, is focused on the development and commercialization of innovative medicines that provide unique and meaningful advantages to people with kidney disease. The Keryx team consists of approximately 200 committed people working with passion to advance the care of people with this complex disease. This dedication has resulted in two FDA-approved indications for Keryx’s first medicine, Auryxia® (ferric citrate) tablets. For more information about Keryx, please visit www.keryx.com. About BioVectra BioVectra is a CDMO that serves pharmaceutical and biotech companies with full-service cGMP outsourcing solutions for intermediates and active pharmaceutical ingredients. An innovative and reliable service partner with a strong regulatory history, BioVectra has over 45 years of experience specializing in:  GMP Microbial Fermentation & Purification  Complex Chemistry  Process & Analytical Development For more information about BioVectra, please visit www.biovectra.com. Media Contact Jordan MacGregor Marketing and Communications Manager [email protected] 902-566-9116 ext. 6376 www.biovectra.com]]>